Cooper D G, Durant G J, Ganellin C R, Ife R J, Meeson M L, Sach G S
Smithkline Beecham Research, Hertfordshire England.
Farmaco. 1991 Jan;46(1):3-19.
For a series of 2-(pyridin-2-ylbutylamino)-5-(3-picolinylmethyl)pyrimidin- 4(1H)-ones (isocytosines) substituted in the pyridine 3-position, activity as H1- and H2-receptor histamine antagonists appears to correlate with the size of the 3-substituent. Steric interaction between the substituent and the butyl chain is explored by conformational analysis using Molecular Mechanics and Molecular Orbital calculations on 2-propyl- and 2-propyl-3-methyl-pyridines; it appears that the substituent may alter activity by changing the preferred conformation of the drug. This observation is extended by synthesis of a semirigid bicyclic analogue wherein 3-methylpyridinylbutyl is replaced by tetrahydroquinolinylpropyl. This compound is 2-3 times more potent as an H1-receptor antagonist confirming that a trans/trans conformation favours activity. Although derived from an H2-antagonist structure, the compound is not an antagonist at histamine H2 receptors thus proving that the conformational requirements are different at H1 and H2 receptors.
对于一系列在吡啶3-位被取代的2-(吡啶-2-基丁基氨基)-5-(3-吡啶甲基)嘧啶-4(1H)-酮(异胞嘧啶),作为H1和H2受体组胺拮抗剂的活性似乎与3-取代基的大小相关。通过使用分子力学和分子轨道计算对2-丙基吡啶和2-丙基-3-甲基吡啶进行构象分析,研究了取代基与丁基链之间的空间相互作用;似乎取代基可能通过改变药物的优势构象来改变活性。通过合成一种半刚性双环类似物扩展了这一观察结果,其中3-甲基吡啶基丁基被四氢喹啉基丙基取代。该化合物作为H1受体拮抗剂的效力高2至3倍,证实反式/反式构象有利于活性。尽管该化合物源自H2拮抗剂结构,但它不是组胺H2受体的拮抗剂,因此证明H1和H2受体的构象要求不同。